Real-World Evidence for Value-Based HTA: Unlocking Affordable Access to Chronic Disease Care in Asia-Pacific
Moderator
Bor-Sheng Ko, PhD, MD, National Taiwan University Hospital, New Taipei City, Taiwan
Speakers
Juliana N Lui, PhD, The Chinese University of Hong Kong, Hong Kong, China; Fei-Yuan Sharon Hsiao, PhD, College of Medicine, National Taiwan University, Taipei, Taiwan; Elise Chia Hui Tan, MHA, MS, PhD, China Medical University, Taiwan, Taichung, Taiwan
Chronic diseases such as diabetes and cardiovascular disease account for most long-term healthcare spending. However, reimbursement and clinical decisions are often based on short-term trials, creating uncertainty of long-term effectiveness, safety, and budget impact. As health systems face fiscal pressure while ensuring timely access to innovation, real-world evidence (RWE) is essential for complementing trial data and mitigating decision uncertainty.
In this context, disease registries and population-level EHR or claims databases offer complementary strengths. Integrating these sources strengthens comparative effectiveness and economic modeling, supporting more sustainable, value-based Health Technology Assessment (HTA) and coverage decisions.
This 60-minute workshop will examine how RWE infrastructures in Hong Kong and Taiwan inform HTA, reimbursement, and clinical decision-making in chronic disease management.
The session will begin with a brief overview (5 minutes) of evolving HTA needs in Asia, highlighting uncertainty in coverage decisions and the complementary role of RWE in informing them.
A first case example (15 minutes) will present Hong Kong’s integration of the Hong Kong Diabetes Register with territory-wide EHR data to support longitudinal outcome assessment, risk prediction, and lifetime patient-level cost-effectiveness modeling for reimbursement decisions.
The panel will then examine Taiwan’s national ASCVD initiative (15 minutes), where nationwide claims data identified gaps in lipid management, informing risk-stratified clinical pathways and a National Health Insurance reimbursement pay-for-performance program.
A third presentation (15 minutes) will discuss RWE on changes in metabolic syndrome prevention from a Primary Care–Based National Lifestyle Intervention Program and its implications for effectiveness and prevention policy.
The session will conclude with a 10-minute moderated discussion on methodological, governance, and implementation considerations in embedding RWE into HTA and coverage frameworks.
Topic
Clinical Outcomes, Health Policy & Regulatory, Real World Data & Information Systems